CPT Codes for SARS-CoV-2 Vaccines and Immunization Administration

The CPT Editorial Panel has developed several new SARS-CoV-2 vaccine product and immunization administration codes. This will be an on-going process as new vaccines are approved and released on the market. The new CPT codes clinically distinguish each coronavirus vaccine product for better tracking, reporting, and analysis that supports data-driven planning and allocation. Importantly, these CPT codes are available prior to the public availability of the vaccines to facilitate updating of health care electronic systems across the US. The new immunization administration codes are both distinct to each coronavirus vaccine and the specific dose in the required schedule. This level of specificity is a first for vaccine CPT codes, but offers the ability to track each vaccine dose, even when the vaccine product is not reported (eg, when the vaccine may be given to the patient for free). These CPT codes report the actual work of administering the vaccine, in addition to all necessary counseling provided to patients or caregivers and updating the electronic record. Note you will <u>not</u> report the immunization administration codes in the current CPT code book (90460-90461, 90471-90474) when administering a COVID vaccine.

Note: All new vaccine-specific CPT codes will be available for use and effective upon each new coronavirus vaccine receiving Emergency Use Authorization or approval from the Food and Drug Administration.

		CPT Codes					
Vaccine Product Information	Vaccine Manufacturer	Product	1 st Dose Admin	2 nd Dose Admin	3 rd Dose Admin	Booster Admin	Patient Age
SARS-CoV-2 (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, PF, 30 mcg/ 0.3mL dosage, diluent reconstituted, for IM use	<u>Pfizer, Inc</u>	91300	0001A	0002A	0003A	0004A	≥12 years
SARS-CoV-2 (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, PF, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for IM use	Pfizer, Inc	91305 N	0051A	0052A	0053A	0054A	
SARS-CoV-2 (coronavirus disease [COVID- 19]) vaccine, mRNA-LNP, spike protein, PF, 10 mcg/0.2 mL dosage , diluent reconstituted, tris-sucrose formulation, for IM use	Pfizer, Inc	91307 💉	0071A	0072A	N/A	N/A	5-11 years
SARS-CoV-2 (Coronavirus disease [COVID- 19]) vaccine, mRNA-LNP, spike protein, PF, 100 mcg/0.5mL dosage, for IM use	<u>Moderna,</u> <u>Inc</u>	91301	0011 A	0012 A	0013 A	N/A	≥18 years
SARS-CoV-2 (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, PF, 5x10 ¹⁰ viral particles/0.5mL dosage, for IM use	AstraZeneca, Plc	91302 📈	0021A	0022A	N/A	N/A	
SARS-CoV-2 (coronavirus disease [COVID- 19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, PF, 5x1010viral particles/ 0.5mL dosage, for IM use	<u>Janssen</u>	91303	0031A	N/A	N/A	N/A	≥18 years
SARS-CoV-2 (coronavirus disease [COVID- 19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, PF, 5 mcg/0.5 mL dosage, for IM use	Novavax, Inc	91304 🖊	0041A	0042A	N/A	N/A	

Indicates pending FDA approval.

Links to ACIP recommendations are embedded in the vaccine manufacturer when available.

Abbreviations: Admin, administration; IM, intramuscular; PF, preservative free, SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2

While the COVID-19 immunization administration (IA) codes do appear on the 2021 Medicare Physician Fee Schedule (MPFS), their RUC-recommended RVUs are not published since they are assigned Status Indicator 'X' (X = Statutory exclusion. These codes represent an item or service that is not in the statutory definition of "physician services" for fee schedule payment purposes. No RVUS or payment amounts are shown for these codes, and no payment may be made under the physician fee schedule (examples are ambulance services and clinical diagnostic laboratory services).